학술논문
From bone to breast and back - the bone cytokine RANKL and breast cancer
Document Type
Academic Journal
Source
Breast Cancer Research. May 25, 2011, Vol. 13 Issue 3
Subject
Language
English
ISSN
1465-5411
Abstract
Author(s): Lorenz C Hofbauer[sup.1,2] , Tilman D Rachner[sup.1] and Christine Hamann[sup.3] Breast cancer and osteoporotic fractures affect one in eight and one in three women, respectively, during lifetime, ranking these [...]
Receptor activator of nuclear factor-κB ligand (RANKL) plays a pivotal role in regulating bone homeostasis. Osteoporosis and malignant bone disease secondary to breast cancer are characterized by enhanced RANKL production and increased bone turnover. Thus, denosumab, a monoclonal antibody to RANKL, has been developed and is now approved for various bone loss conditions. Recent results indicate that RANKL may also promote the development and osseous migration of breast cancer.
Receptor activator of nuclear factor-κB ligand (RANKL) plays a pivotal role in regulating bone homeostasis. Osteoporosis and malignant bone disease secondary to breast cancer are characterized by enhanced RANKL production and increased bone turnover. Thus, denosumab, a monoclonal antibody to RANKL, has been developed and is now approved for various bone loss conditions. Recent results indicate that RANKL may also promote the development and osseous migration of breast cancer.